Janney Montgomery Scott LLC lowered its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 21.0% in the fourth quarter, ...

Benzinga's options scanner just detected over 16 options trades for Moderna (NASDAQ:MRNA) summing a total amount of $1,134,726. At the same time, our algo caught 10 for a total amount of 1,113,875.

Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives ...

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before the opening bell. In the last reported quarter, MRNA’s earnings beat ...

Valued at $13.1 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage pharmaceutical company. It focuses on discovering and developing messenger ...

In contrast to shares of AbbVie and Gilead Sciences, which have been strong performers to kick off 2025, Moderna (NASDAQ: MRNA) stands out as a turnaround opportunity. The company, recognized for ...

Healthcare company Moderna is an example of a business that I see as blowing a huge opportunity to diversify in recent years. It generated billions in revenue from its successful COVID vaccine ...

Inflation data, Powell testimony, more earnings will be in focus this week. • Robinhood’s strong financial health, robust ...

Stocks recently featured in the blog include: Amgen AMGN, CRISPR Therapeutics CRSP, Moderna MRNA, Sarepta Therapeutics SRPT and Vertex Pharmaceuticals VRTX. Here are highlights from Wednesday’s ...

Moderna Inc. dropped its share prices by 17 percent last week to finish at $32.6 from the $39.42 registered on January 31 as ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other ...

Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the strategy for ...